PENGARUH PEMBERIAN ERDOSTEIN TERHADAP KAPASITAS FISIK DAN KUALITAS HIDUP PENDERITA PENYAKIT PARU OBSTRUKTIF KRONIK STABIL
| Main Authors: | , Rachman Edi Santoso, , dr. Bambang Sigit Riyanto, Sp.PD, K-P |
|---|---|
| Format: | Thesis NonPeerReviewed |
| Terbitan: |
[Yogyakarta] : Universitas Gadjah Mada
, 2014
|
| Subjects: | |
| Online Access: |
https://repository.ugm.ac.id/134039/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=74998 |
Daftar Isi:
- Background: Erdostein is a mucolytic drug commonly used for COPD patients, which also has systemic antiinflammation and antioxidant effect. These systemic effects are expected to increase physical capacity and quality of life. The aim of this research is to determine the effect of erdostein on physical capacity and quality of life in COPD patients. Methods: The research is a randomized controlled trial, which comparing add-on therapy using erdostein 300 mg bid versus plasebo, for 30 days, combined with COPD standard treatments. Patients are recruited at RSKP Respira Yogyakarta outpatient clinics. Diagnosis are confirmed using spirometri based on GOLD criteria. The 6MWT distances are measured at baseline, day 11, and at the end of study. The SGRQ scores are measured at baseline and at the end of study. Result: Thirty eligible COPD patients are recruited, and randomly assigned to either erdostein group or plasebo group. One patient from each group was excluded. There 28 subjects (100% men, mean age 64.25±9.14 years, mean FEV1% 45±12.15 %) who completed the study. Baseline characteristics were similar between two groups. There were significant increases in 6MWT distance in erdostein group vs plasebo at day 11 (29.79±23.18 vs 0.29±31.13 meters, p=0.009) and at the end of study (36.93±26.49 vs 11.50±33.74 meters, p=0.036). SGRQ total score decline was better in erdostein group compared to plasebo (-12.59±12.79 vs -2.31±7.58, p=0,016). Conclusion: Add-on therapy using erdostein 300 mg bid for 30 days could increase physical capacity (6MWT range) and quality of life (SGRQ scores) in COPD patients